The Challenge of Clinical Control in Acromegaly

Managing acromegaly effectively requires balancing biochemical targets with patient-reported outcomes. A recent study evaluated the use of Octreotide LAR in acromegaly compared to lanreotide autogel, focusing on clinical control as measured by the SAGIT instrument. Historically, biochemical markers like GH and IGF-1 have served as the primary treatment objectives. However, these levels do not always reflect the complex symptoms patients experience. Consequently, clinicians are increasingly adopting multi-dimensional tools to better assess disease evolution and improve decision-making.

The SAGIT instrument provides a holistic framework by evaluating five key domains: Signs and symptoms (S), Associated comorbidities (A), Growth hormone levels (G), IGF-1 levels (I), and Tumor profile (T). By using this standardized approach, healthcare providers can identify subtle clinical progressions that biochemical tests alone might miss. Moreover, this tool helps bridge the gap between laboratory data and the patient's lived experience with the disease.

Clinical Outcomes of Octreotide LAR in Acromegaly

Researchers conducted an observational study at a referral hospital in Mexico to compare the two leading somatostatin analogues. The study included 26 patients, with 50% receiving lanreotide autogel and approximately 42% receiving octreotide LAR. Notably, the researchers found that biochemical control, defined by IGF-1 levels, occurred in 42.3% of the cohort. However, when they applied the SAGIT instrument, only 30.7% of patients met the criteria for true clinical control. This discrepancy highlights that biochemical stability does not always equal clinical remission.

Specifically, the results demonstrated that patients treated with octreotide LAR achieved significantly higher rates of disease control according to SAGIT scores compared to those on lanreotide autogel (p = 0.043). Therefore, the study suggests that octreotide LAR may offer superior efficacy in managing the multifaceted aspects of acromegaly. Furthermore, the authors recommend the preferential use of octreotide LAR in resource-limited settings to maximize clinical benefit. Although both treatments are common, this evidence points toward a clear advantage for octreotide LAR in achieving comprehensive disease stability.

FAQs

What is the SAGIT instrument in acromegaly?

SAGIT is a clinician-reported outcome tool that evaluates Signs and symptoms, Associated comorbidities, GH levels, IGF-1 levels, and Tumor profile to provide a comprehensive assessment of disease activity.

Why is clinical control different from biochemical control?

Biochemical control focuses strictly on GH and IGF-1 levels, while clinical control, as measured by SAGIT, accounts for physical symptoms and comorbidities that may persist even when hormone levels appear normal.

Which medication showed better results in the SAGIT study?

According to the recent research, octreotide LAR demonstrated significantly better disease control than lanreotide autogel when evaluated using the comprehensive SAGIT tool.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Núñez-Martínez FJ et al. [Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT]. Rev Med Inst Mex Seguro Soc. 2026 May 06. doi: 10.5281/zenodo.18715331. PMID: 42090715.

Giustina A, et al. SAGIT: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary. 2016 Feb;19(1):1-10.

Melmed S, et al. International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. J Clin Endocrinol Metab. 2021 Jul 27;106(9):2544-2556.